This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2006 Oct;11(5):143.

doi: 10.1136/ebm.11.5.143.

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Kenneth A Ballew¹

Affiliations

PMID: 17213145
DOI: 10.1136/ebm.11.5.143

Comment

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Kenneth A Ballew. Evid Based Med. 2006 Oct.

. 2006 Oct;11(5):143.

doi: 10.1136/ebm.11.5.143.

Author

Kenneth A Ballew¹

Affiliation

¹ University of Virginia, Charlottesville, Virginia, USA.

PMID: 17213145
DOI: 10.1136/ebm.11.5.143

No abstract available

PubMed Disclaimer

Comment on

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Bhatt DL, et al. N Engl J Med. 2006 Apr 20;354(16):1706-17. doi: 10.1056/NEJMoa060989. Epub 2006 Mar 12. N Engl J Med. 2006. PMID: 16531616 Clinical Trial.

Similar articles

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high-risk atherothrombosis.
Ballew KA. Ballew KA. ACP J Club. 2006 Sep-Oct;145(2):33. ACP J Club. 2006. PMID: 16944853 No abstract available.
Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence.
Aronow WS. Aronow WS. Geriatrics. 2007 Apr;62(4):12-24. Geriatrics. 2007. PMID: 17408314 Review.
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Bhatt DL, et al. Am Heart J. 2004 Aug;148(2):263-8. doi: 10.1016/j.ahj.2004.03.028. Am Heart J. 2004. PMID: 15308995 Clinical Trial.
Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P, Sechenova O, Hennekens CH. Gorelick P, et al. J Cardiovasc Pharmacol Ther. 2006 Dec;11(4):245-8. doi: 10.1177/1074248406296862. J Cardiovasc Pharmacol Ther. 2006. PMID: 17220470 Review.
Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
Fisher M. Fisher M. Arch Neurol. 2006 Jan;63(1):20-4. doi: 10.1001/archneur.63.1.20. Arch Neurol. 2006. PMID: 16401733 Review.

See all similar articles

Cited by

Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy.
Altman R. Altman R. Thromb J. 2007 Aug 29;5:11. doi: 10.1186/1477-9560-5-11. Thromb J. 2007. PMID: 17727726 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.